Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

The orphan nuclear receptor RORα and group 3 innate lymphoid cells drive fibrosis in a mouse model of Crohn's disease.

Lo BC, Gold MJ, Hughes MR, Antignano F, Valdez Y, Zaph C, Harder KW, McNagny KM.

Sci Immunol. 2016 Sep 2;1(3):eaaf8864. doi: 10.1126/sciimmunol.aaf8864. Epub 2016 Sep 2.

PMID:
28783681
2.

The orphan nuclear receptor ROR alpha and group 3 innate lymphoid cells drive fibrosis in a mouse model of Crohn's disease.

Lo BC, Gold MJ, Hughes MR, Antignano F, Valdez Y, Zaph C, Harder KW, McNagny KM.

Sci Immunol. 2016 Sep 2;1(3). pii: eaaf8864. doi: 10.1126/sciimmunol.aaf8864.

3.

2B4-SAP signaling is required for the priming of naive CD8+ T cells by antigen-expressing B cells and B lymphoma cells.

Huang YH, Tsai K, Tan SY, Kang S, Ford ML, Harder KW, Priatel JJ.

Oncoimmunology. 2016 Dec 27;6(2):e1267094. doi: 10.1080/2162402X.2016.1267094. eCollection 2017.

4.

Targeting Lyn regulates Snail family shuttling and inhibits metastasis.

Thaper D, Vahid S, Nip KM, Moskalev I, Shan X, Frees S, Roberts ME, Ketola K, Harder KW, Gregory-Evans C, Bishop JL, Zoubeidi A.

Oncogene. 2017 Jul 13;36(28):3964-3975. doi: 10.1038/onc.2017.5. Epub 2017 Mar 13.

PMID:
28288135
5.

Lyn deficiency leads to increased microbiota-dependent intestinal inflammation and susceptibility to enteric pathogens.

Roberts ME, Bishop JL, Fan X, Beer JL, Kum WW, Krebs DL, Huang M, Gill N, Priatel JJ, Finlay BB, Harder KW.

J Immunol. 2014 Nov 15;193(10):5249-63. doi: 10.4049/jimmunol.1302832. Epub 2014 Oct 22.

6.

Lyn activity protects mice from DSS colitis and regulates the production of IL-22 from innate lymphoid cells.

Bishop JL, Roberts ME, Beer JL, Huang M, Chehal MK, Fan X, Fouser LA, Ma HL, Bacani JT, Harder KW.

Mucosal Immunol. 2014 Mar;7(2):405-16. doi: 10.1038/mi.2013.60. Epub 2013 Sep 18.

PMID:
24045577
7.

Dysregulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and hox gene expression in hematopoietic cells.

Sio A, Chehal MK, Tsai K, Fan X, Roberts ME, Nelson BH, Grembecka J, Cierpicki T, Krebs DL, Harder KW.

Cancer Res. 2013 Oct 1;73(19):5892-904. doi: 10.1158/0008-5472.CAN-13-0842. Epub 2013 Aug 1.

8.

Genetic interdependence of Lyn and negative regulators of B cell receptor signaling in autoimmune disease development.

Tsantikos E, Maxwell MJ, Kountouri N, Harder KW, Tarlinton DM, Hibbs ML.

J Immunol. 2012 Aug 15;189(4):1726-36. doi: 10.4049/jimmunol.1103427. Epub 2012 Jul 13.

9.

Phosphatidylinositol-3 kinase activity in B cells is negatively regulated by Lyn tyrosine kinase.

Xu Y, Huntington ND, Harder KW, Nandurkar H, Hibbs ML, Tarlinton DM.

Immunol Cell Biol. 2012 Oct;90(9):903-11. doi: 10.1038/icb.2012.31. Epub 2012 Jul 10.

PMID:
22777522
10.

Lyn-dependent signaling regulates the innate immune response by controlling dendritic cell activation of NK cells.

Krebs DL, Chehal MK, Sio A, Huntington ND, Da ML, Ziltener P, Inglese M, Kountouri N, Priatel JJ, Jones J, Tarlinton DM, Anderson GP, Hibbs ML, Harder KW.

J Immunol. 2012 May 15;188(10):5094-105. doi: 10.4049/jimmunol.1103395. Epub 2012 Apr 9.

11.

The role of the Src family kinase Lyn in the immunomodulatory activities of cathelicidin peptide LL-37 on monocytic cells.

Nijnik A, Pistolic J, Cho P, Filewod NC, Falsafi R, Ramin A, Harder KW, Hancock RE.

J Leukoc Biol. 2012 Apr;91(4):599-607. doi: 10.1189/jlb.0411191. Epub 2012 Jan 13.

12.

Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases.

Shio MT, Eisenbarth SC, Savaria M, Vinet AF, Bellemare MJ, Harder KW, Sutterwala FS, Bohle DS, Descoteaux A, Flavell RA, Olivier M.

PLoS Pathog. 2009 Aug;5(8):e1000559. doi: 10.1371/journal.ppat.1000559. Epub 2009 Aug 21. Erratum in: PLoS Pathog. 2009 Sep;5(9). doi: 10.1371/annotation/abca067d-b82b-4de6-93c5-0fcc38e3df05. Tiemi Shio, Marina [corrected to Shio, Marina Tiemi].

13.

Perturbation of the CD4 T cell compartment and expansion of regulatory T cells in autoimmune-prone Lyn-deficient mice.

Tsantikos E, Quilici C, Harder KW, Wang B, Zhu HJ, Anderson GP, Tarlinton DM, Hibbs ML.

J Immunol. 2009 Aug 15;183(4):2484-94. doi: 10.4049/jimmunol.0804346. Epub 2009 Jul 20.

14.

Chronic immunodeficiency in mice lacking RasGRP1 results in CD4 T cell immune activation and exhaustion.

Priatel JJ, Chen X, Zenewicz LA, Shen H, Harder KW, Horwitz MS, Teh HS.

J Immunol. 2007 Aug 15;179(4):2143-52.

15.

Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2.

McColl BK, Paavonen K, Karnezis T, Harris NC, Davydova N, Rothacker J, Nice EC, Harder KW, Roufail S, Hibbs ML, Rogers PA, Alitalo K, Stacker SA, Achen MG.

FASEB J. 2007 Apr;21(4):1088-98. Epub 2007 Jan 22.

PMID:
17242158
16.

Csk-binding protein mediates sequential enzymatic down-regulation and degradation of Lyn in erythropoietin-stimulated cells.

Ingley E, Schneider JR, Payne CJ, McCarthy DJ, Harder KW, Hibbs ML, Klinken SP.

J Biol Chem. 2006 Oct 20;281(42):31920-9. Epub 2006 Aug 18.

17.

The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling.

Hibbs ML, Harder KW.

Growth Factors. 2006 Jun;24(2):137-49.

PMID:
16801133
18.

Lyn-deficient mice develop severe, persistent asthma: Lyn is a critical negative regulator of Th2 immunity.

Beavitt SJ, Harder KW, Kemp JM, Jones J, Quilici C, Casagranda F, Lam E, Turner D, Brennan S, Sly PD, Tarlinton DM, Anderson GP, Hibbs ML.

J Immunol. 2005 Aug 1;175(3):1867-75.

19.

Lyn tyrosine kinase: accentuating the positive and the negative.

Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM.

Immunity. 2005 Jan;22(1):9-18. Review.

20.

Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1.

Harder KW, Quilici C, Naik E, Inglese M, Kountouri N, Turner A, Zlatic K, Tarlinton DM, Hibbs ML.

Blood. 2004 Dec 15;104(13):3901-10. Epub 2004 Aug 31.

PMID:
15339845
21.

Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase.

Odom S, Gomez G, Kovarova M, Furumoto Y, Ryan JJ, Wright HV, Gonzalez-Espinosa C, Hibbs ML, Harder KW, Rivera J.

J Exp Med. 2004 Jun 7;199(11):1491-502. Epub 2004 Jun 1.

22.

Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos.

Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D, Small C, Weinberg RA, Sizeland AM, Zhu HJ.

Mol Cell Biol. 2003 Jun;23(12):4371-85.

23.

Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity.

Hibbs ML, Harder KW, Armes J, Kountouri N, Quilici C, Casagranda F, Dunn AR, Tarlinton DM.

J Exp Med. 2002 Dec 16;196(12):1593-604.

24.

The activation and subsequent regulatory roles of Lyn and CD19 after B cell receptor ligation are independent.

Xu Y, Beavitt SJ, Harder KW, Hibbs ML, Tarlinton DM.

J Immunol. 2002 Dec 15;169(12):6910-8.

25.

Constitutive activation of the SRC family kinase Hck results in spontaneous pulmonary inflammation and an enhanced innate immune response.

Ernst M, Inglese M, Scholz GM, Harder KW, Clay FJ, Bozinovski S, Waring P, Darwiche R, Kay T, Sly P, Collins R, Turner D, Hibbs ML, Anderson GP, Dunn AR.

J Exp Med. 2002 Sep 2;196(5):589-604.

26.

Gain control of N-methyl-D-aspartate receptor activity by receptor-like protein tyrosine phosphatase alpha.

Lei G, Xue S, Chéry N, Liu Q, Xu J, Kwan CL, Fu YP, Lu YM, Liu M, Harder KW, Yu XM.

EMBO J. 2002 Jun 17;21(12):2977-89.

27.

Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage.

Harder KW, Parsons LM, Armes J, Evans N, Kountouri N, Clark R, Quilici C, Grail D, Hodgson GS, Dunn AR, Hibbs ML.

Immunity. 2001 Oct;15(4):603-15.

28.

Protein-tyrosine phosphatase alpha regulates Src family kinases and alters cell-substratum adhesion.

Harder KW, Moller NP, Peacock JW, Jirik FR.

J Biol Chem. 1998 Nov 27;273(48):31890-900.

29.

CD45 and RPTPalpha display different protein tyrosine phosphatase activities in T lymphocytes.

Ng DH, Jabali MD, Maiti A, Borodchak P, Harder KW, Brocker T, Malissen B, Jirik FR, Johnson P.

Biochem J. 1997 Nov 1;327 ( Pt 3):867-76.

30.

Comparison of the specificity of bacterially expressed cytoplasmic protein-tyrosine phosphatases SHP and SH-PTP2 towards synthetic phosphopeptide substrates.

Dechert U, Affolter M, Harder KW, Matthews J, Owen P, Clark-Lewis I, Thomas ML, Aebersold R, Jirik FR.

Eur J Biochem. 1995 Aug 1;231(3):673-81.

31.
32.

A widely distributed putative mammalian transcriptional regulator containing multiple paired amphipathic helices, with similarity to yeast SIN3.

Halleck MS, Pownall S, Harder KW, Duncan AM, Jirik FR, Schlegel RA.

Genomics. 1995 Mar 20;26(2):403-6.

PMID:
7601471
33.

Non-radioactive method to measure CD45 protein tyrosine phosphatase activity isolated directly from cells.

Ng DH, Harder KW, Clark-Lewis I, Jirik F, Johnson P.

J Immunol Methods. 1995 Feb 27;179(2):177-85.

PMID:
7533193
34.

Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A.

Roberge M, Tudan C, Hung SM, Harder KW, Jirik FR, Anderson H.

Cancer Res. 1994 Dec 1;54(23):6115-21.

35.
36.
37.

Molecular cloning, expression, and characterization of the human mitogen-activated protein kinase p44erk1.

Charest DL, Mordret G, Harder KW, Jirik F, Pelech SL.

Mol Cell Biol. 1993 Aug;13(8):4679-90.

38.

The gene for receptor-like protein tyrosine phosphatase (PTPRB) is assigned to chromosome 12q15-->q21.

Harder KW, Anderson LL, Duncan AM, Jirik FR.

Cytogenet Cell Genet. 1992;61(4):269-70.

PMID:
1486802
39.
40.

Cloning and chromosomal assignment of a widely expressed human receptor-like protein-tyrosine phosphatase.

Jirik FR, Janzen NM, Melhado IG, Harder KW.

FEBS Lett. 1990 Oct 29;273(1-2):239-42.

Supplemental Content

Loading ...
Support Center